Neeraj Agarwal summarizes some Abstracts of ASCO24

Neeraj Agarwal shared on X:

Abstract #5010 by Michael Morris

• Phase 1 study of Actinium-225-labeled antibody (JNJ-6420) targeting human kallikrein 2 in prostate cancer
• 1-2 doses elicited encouraging PSA and radiographic responses .

Abstract #5020 by Arun Azad

• Phase 3 TALAPRO-2 trial of 1L enza plus talazo vs. enza in mCRPC prostate cancer
• Increased baseline ctDNA burden had poor prognosis and ctDNA conversion from high to low at week 9
• Predicted improved rPFS

Abstract #5055 by Edmond Kwan

• In TheraP phase 2 trial of Lu-177 vs. cabazitaxel in mCRPC prostate cancer
• Higher ctDNA fraction associated with decreased PSMA expression, increased FDG uptake, and decreased response to Lu-177

Abstract #5079 by Ronan McLaughlin

• Analysis of ENZAMET phase 3 trial in mHSPC prostate cancer
• PSA nadir ≤0.2ng/ml at 7 months associated with longer OS across all subgroups and treatment arms, validates SWOG data

Abstract #5001 by Matthew Smith

• In Phase 3 CYCLONE 2 trial in mCRPC Abemaciclib plus abi vs abi did not improve outcomes, questioning the role of CDK4/6 inhibition

Abstract #5005 by Stephen Freedland

• EMBARK phase 3 trial in patients with BCR prostate cancer
• Treatment suspension leads to clinically meaningful improvements in HRQoL

Abstract #5007 by Susan Halabi

• A novel prognostic clinical-genetic model (including ctDNA) in mCRPC classifies patients into separate risk groups
• may help patient selection for trials

Abstract #5008 by Johann De Bono

• Baseline ctDNA analyses in Phase 3 PSMA fore trial in patients with mCRPC
• ctDNA>1%, AR, TP53 and PTEN alteration associated with rPFS, PSA50 and ORR in both arms

Abstract #5003 by Karim Fizazi

• Phase 3 PSMAfore trial in taxane-naïve patients with mCRPC
• Lu-177 delayed time to worsening of self-reported pain and HRQoL vs. 2nd ARPI

Abstract #1500 by Marissa Buchan

• AI-based virtual dietitian assistance for patients with cancer
• improved diet, QoL and symptom control with AI-assistance

Abstract #1508 by Shruthi Perati

• Patients with Medicaid or higher neighborhood social vulnerability, especially among Black patients less likely to enroll in trials.
• Need for policies to mitigate these disparities

Abstract #11005 by Justin M. Barnes

• High deductible health plans among cancer survivors
• Associated with worse OS and cancer survival

Abstract #12001 by Kyoko Obama

• Randomized controlled trial of App-based program vs usual care in patients with advanced cancer
• improved communication in the App group without exacerbating patients’ psychological distress

Abstract #1503 by Robert Daly

• RCT of Integrative Medicine at Home (IM at Home: virtual live mind-body and fitness class) vs. Enhanced Usual Care
• IM at Home reduces and shortens hospitalization

Abstract #4510 by Jae Lyun Lee

• ULTIMA phase 2 trial of modified FOLFIRINOX for 1L treatment of patients with advanced urachal cancer
• Encouraging outcomes with ORR 61.9%, mPFS 9.3 months and mOS 26.4 months

Abstract #4566 by Joaquim Bellmunt

• In JAVELIN Bladder 100 Phase 3 trial of avelumab maintenance vs. supportive care in patients with low tumor burden bladder cancer
• Increased long terms efficacy and manageable AEs

Abstract #4506 by Laurence Albiges

• Phase 2 IMmotion010 trial of adjuvant atezolizumab vs. placebo kidney cancer
• Increased baseline serum KIM-1 levels leads to poorer prognosis and increased outcomes with atezolizumab vs. placebo

Abstract #4512 by Sahil Doshi

• Analysis of outcomes with 1L systemic treatment in chromophobe mRCC
• Targeted doublet regimens increased TTF and OS compared to monotherapies

Abstract #4533 by Rana McKay

• Matched tissue and ctDNA analysis in real-world database of kidney cancer
• Increased mutation detection in ctDNA and increased concordance between ctDNA and tissue CGP in patients with metastases

Find more abstract summaries by Neeraj Agarwal on his X/Twitter page.

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah.

He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.